



ARSEUS
Driving superior care

Press Release

Regulated information

DISCLOSURE OF RECEIVED NOTIFICATION

Waregem (Belgium) / Rotterdam (Netherlands)¹, 14 April 2014 – Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Arseus NV received notifications on 10 April 2014 from Fidelity Management and Research (FMR LLC) and on 11 April 2014 from Enhold NV concerning the acquisition or disposal of voting securities.

On 10 April the shareholding of Fidelity Management and Research crossed the disclosure threshold of 3% through the acquisition of voting securities. Enhold NV has announced via a press release on 9 April, and a notification received on 11 April, that it has sold all of the shares it held in Arseus.

Based on the denominator of 31,358,358 (total number of voting rights) and the relevant notifications that Arseus received, the shareholder structure as of 11 April 2014 is as follows:

	Number of shares	% of effective voting rights
BNP Paribas Investment Partners SA	1,609,182	5.13%
Fidelity Management and Research (FMR LLC)	1,223,000	3.90%
JP Morgan Asset Management UK Ltd.	946,804	3.02%
Alychlo NV/ Coucke	653,376	2.08%
Arseus NV (treasury shares)	881,378	2.81%
Public	26,044,618	83.06%
Total	31,358,358	100.00%

The original notification forms are available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

¹ This press release was sent out by Arseus NV and Arseus BV.

For more information:

Marieke Palstra

Director Investor Relations

+31 88 33 11 213 (Office)

marieke.palstra@arseus.com

Arseus profile

Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.